IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 3481 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
  Search
 
   Next article
   Previous article 
   Table of Contents
  
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Article in PDF (91 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

 
  In this article
   References
   Article Tables

 Article Access Statistics
    Viewed5301    
    Printed99    
    Emailed5    
    PDF Downloaded187    
    Comments [Add]    
    Cited by others 17    

Recommend this journal

 


 
LETTER TO EDITOR
Year : 2005  |  Volume : 71  |  Issue : 4  |  Page : 288-289

Imatinib induced Stevens-Johnson syndrome: Lack of recurrence following re-challenge with a lower dose


1 Department of Medical Oncology, Amrita Institute of Medical Sciences, Elamakkara, Kochi, India
2 CSI Medical College, Karakkonam, Trivandrum, India

Correspondence Address:
Keechilat Pavithran
Department of Medical Oncology, Amrita Institute of Medical Sciences, Elamakkara, Kochi-682 026
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0378-6323.16628

Rights and Permissions



How to cite this article:
Pavithran K, Thomas M. Imatinib induced Stevens-Johnson syndrome: Lack of recurrence following re-challenge with a lower dose. Indian J Dermatol Venereol Leprol 2005;71:288-9

How to cite this URL:
Pavithran K, Thomas M. Imatinib induced Stevens-Johnson syndrome: Lack of recurrence following re-challenge with a lower dose. Indian J Dermatol Venereol Leprol [serial online] 2005 [cited 2019 Oct 16];71:288-9. Available from: http://www.ijdvl.com/text.asp?2005/71/4/288/16628


Sir,

Imatinib mesylate (STI-571) is a selective and potent small-molecule inhibitor of tyrosine kinases, including BCR-ABL fusion protein, c-Kit and platelet-derived growth factor receptor. It is the most active agent for the treatment of chronic myeloid leukemia (CML), and gastrointestinal stromal tumors. Cutaneous reactions to imatinib therapy are increasingly being recognized, with 5% of these reactions being severe. Though a variety of dermatological manifestations have been described, occurrence of Stevens-Johnson syndrome is rare.

A 35-year-old man was diagnosed as having Philadelphia-positive chronic myeloid leukemia in the chronic phase. He was started on imatinib 400 mg daily, which was the only medication given. His initial hemogram revealed: hemoglobin, 12.8 g/dl; white blood cell count, 248 x 109/l; and platelet count, 440x 109/l. Complete hematologic remission was achieved with imatinib in two weeks. On the 14th day of treatment, the patient developed an itchy macular eruption mainly over the trunk. Atypical target lesions were observed without areas of necrosis. In addition to the skin lesions, the mucosae were involved with ulcerative lesions. A clinical diagnosis of Stevens-Johnson syndrome was made.

Imatinib was stopped immediately and the patient was given fexofenadine and prednisolone. Healing started within a few days and in one week the lesions cleared. One week following the complete clearance of the rash imatinib was restarted at a dosage of 100 mg daily. This re-challenge at a lower initial dose did not produce any adverse cutaneous reaction. The dose of imatinib was gradually escalated to 400 mg which was continued. Presently, he is in hematologic remission without any untoward side effect.

A variety of adverse cutaneous reactions have been described with imatinib. Of these, rash and edema occur most commonly, the incidence being 66.7% and 65% respectively.[1] Severe and life threatening reactions occur in 5% cases. Reports of cutaneous adverse reactions other than maculo-papular eruptions are rare with imatinib. However, it may cause acute generalized exanthematous pustulosis,[2] oral lichenoid eruption,[3] vasculitis,[4] pseudolymphoma,[5] epidermal necrolysis,[6] hypopigmentation,[7] erythema nodosum,[8] exfoliative dermatitis,[9] and Stevens-Johnson syndrome.[10],[11],[12],[13] Of the four cases of Stevens-Johnson syndrome due to imatinib reported previously, two were males and two females. All these patients, except one, had CML.[10] In two of these cases the lesions reappeared on re-challenge with imatinib.[11],[12] However, our patient, as well as one of the reported cases[10] did not have any recurrence following re-challenge. Clinical characteristics of these patients are shown in [Table - 1]. The etiology of Stevens-Johnson syndrome is not clear and drug-induced cases have been thought to be mediated by an immunological mechanism. Brouard and Saurat have shown that, the incidence of cutaneous reactions with imatinib increases with escalating doses of the drug.[14] Valeyrie et al have reported female sex and imatinib dosage as being independent risk factors for the development of rashes in a multivariate analysis.[1]

As the indications and use of imatinib are increasing, the incidence of adverse cutaneous reactions due to it is likely to increase proportionately. Imatinib induced Stevens-Johnson syndrome being a life threatening reaction, the physician should keep a high index of suspicion for early diagnosis, prompt withdrawal of the drug and institution of appropriate therapy.



 
  References Top

1.Valeyrie L, Bastuji-Garin S, Revuz J, Bachot N, Wechsler J, Berthaud P, et al. Adverse reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: A prospective study of 54 patients. J Am Acad Dermatol 2003;48:201-6.  Back to cited text no. 1  [PUBMED]  [FULLTEXT]  
2.Brouard MC, Prins C, Mach-Pascual S, Saurat JH. Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia. Dermatology 2001;203:57-9.  Back to cited text no. 2  [PUBMED]  [FULLTEXT]  
3.Ena P, Chiarolini F, Siddi GM, Cossu A. Oral lichenoid eruption secondary to imatinib (Glivec). Dermatolog Treat 2004;15:253-5.  Back to cited text no. 3  [PUBMED]  [FULLTEXT]  
4.Hamm M, Touraud JP, Mannone L, Klisnick J, Ponnelle T, Lambert D. Imatinib-induced purpuric vasculitis. Ann Dermatol Venereol 2003;130:765-7.  Back to cited text no. 4  [PUBMED]  [FULLTEXT]  
5.Clark SH, Duvic M, Prieto VG. Mycosis fungoides-like reaction in a patient treated with Gleevec. J Cutan Pathol 2003;30:279-81.  Back to cited text no. 5  [PUBMED]  [FULLTEXT]  
6.Schaich M, Schakel K, Illmer T, Ehninger G, Bornhauser M. Severe epidermal necrolysis after treatment with imatinib and consecutive allogeneic hematopoietic stem cell transplantation. Ann Hematol 2003;82:303-4.   Back to cited text no. 6  [PUBMED]  [FULLTEXT]  
7.Tsao AS, Kantarjian H, Cortes J, O'Brien S, Talpaz M. Imatinib mesylate causes hypopigmentation in the skin. Cancer 2003;98:2483-7.  Back to cited text no. 7  [PUBMED]  [FULLTEXT]  
8.Drummond A, Micallef-Eynaud P, Douglas WS, Hay I, Holyoake TL, Drummond MW. A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec). Br J Haematol 2003;120:911-3.  Back to cited text no. 8  [PUBMED]    
9.Banka N, Aljurf M, Hamadah I. Imatinib (STI-571)-induced exfoliative dermatitis in a Saudi patient with deck chair sign. Dermatology 2003;207:329-30.  Back to cited text no. 9  [PUBMED]  [FULLTEXT]  
10.Sanchez-Gonzalez B, Pascual-Ramirez JC, Fernandez-Abellan P, Belinchon-Romero I, Rivas C, Vegara-Aguilera G. Severe skin reaction to imatinib in a case of Philadelphia-positive acute lymphoblastic leukemia. Blood 2003;101:2446.  Back to cited text no. 10      
11.Hsiao LT, Chung HM, Lin JT, Chiou TJ, Liu JH, Fan FS, et al. Stevens-Johnson syndrome after treatment with STI571: a case report. Br J Haematol 2002;117:620-2.  Back to cited text no. 11  [PUBMED]    
12.Rule SA, O'Brien SG, Crossman LC. Managing cutaneous reactions to imatinib therapy. Blood 2002;100:3434-5.  Back to cited text no. 12  [PUBMED]  [FULLTEXT]  
13.Vidal D, Puig L, Sureda A, Alomar A. STI571-Induced Stevens-Johnson syndrome. Br J Haematol 2002;119:274-5.  Back to cited text no. 13  [PUBMED]    
14.Brouard M, Saurat JH. Cutaneous reactions to STI571. N Engl J Med 2001;345:618-9.  Back to cited text no. 14  [PUBMED]    



 
 
    Tables

  [Table - 1]

This article has been cited by
1 Adverse Skin Effects of Imatinib, a Tyrosine Kinase Inhibitor
M. Pretel-Irazabal,A. Tuneu-Valls,N. Ormaechea-Pérez
Actas Dermo-Sifiliográficas (English Edition). 2014; 105(7): 655
[Pubmed] | [DOI]
2 Life-threatening dermatologic adverse events in oncology
Alyx C. Rosen,Yevgeniy Balagula,Dennis W. Raisch,Vishvas Garg,Beatrice Nardone,Nicole Larsen,Jennifer Sorrell,Dennis P. West,Milan J. Anadkat,Mario E. Lacouture
Anti-Cancer Drugs. 2014; 25(2): 225
[Pubmed] | [DOI]
3 Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience
V. Brazzelli,V. Grasso,G. Borroni
Journal of the European Academy of Dermatology and Venereology. 2013; : n/a
[Pubmed] | [DOI]
4 Efectos adversos cutáneos del imatinib (inhibidor de la tirosín cinasa)
M. Pretel-Irazabal,A. Tuneu-Valls,N. Ormaechea-Pérez
Actas Dermo-Sifiliográficas. 2013;
[Pubmed] | [DOI]
5 Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0
Alice P. Chen,Ann Setser,Milan J. Anadkat,Jonathan Cotliar,Elise A. Olsen,Benjamin C. Garden,Mario E. Lacouture
Journal of the American Academy of Dermatology. 2012; 67(5): 1025
[Pubmed] | [DOI]
6 Advances in the Management of Cutaneous Toxicities of Targeted Therapies
Caroline Robert,Vincent Sibaud,Christine Mateus,Basil S. Cherpelis
Seminars in Oncology. 2012; 39(2): 227
[Pubmed] | [DOI]
7 Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib : Practical approach
IRIS AMITAY-LAISH, SALOMON M. STEMMER, MARIO E. LACOUTURE
Dermatologic Therapy. 2011; 24(4): 386
[VIEW] | [DOI]
8 Uncommon or Delayed Adverse Events Associated With Imatinib Treatment for Chronic Myeloid Leukemia
Rishard Salie, Richard T. Silver
Clinical Lymphoma Myeloma & Leukemia. 2010; 10(5): 331
[VIEW] | [DOI]
9 Efectos secundarios cutáneos de los fármacos antineoplásicos (II): inhibidores de cinasas y anticuerpos monoclonales
Lorena Leal Canosa,María José Fuente González,Miquel Ribera Pibernat
Piel. 2009; 24(8): 427
[Pubmed] | [DOI]
10 Stevens-johnson syndrome induced by combination of imatinib and allopurinol
Hsieh, H.-J., Chan, A.L.F., Lin, S.-J.
Chemotherapy. 2009; 55(4): 197-199
[Pubmed]
11 Secondary cutaneous effects of antineoplastic drugs (II): Kinase inhibitors and monoclonal antibodies | [Efectos secundarios cutáneos de los fármacos antineoplásicos (II): Inhibidores de cinasas y anticuerpos monoclonales]
Canosa, L.L., González, M.J.F., Pibernat, M.R.
Piel. 2009; 24(8): 427-439
[Pubmed]
12 Therapeutic options for chronic myeloid leukemia: Focus on imatinib (Glivec®, Gleevec™)
Henkes, M., van der Kuip, H., Aulitzky, W.E.
Therapeutics and Clinical Risk Management. 2008; 4(1): 163-187
[Pubmed]
13 Chemotherapeutic agents and the skin: An update
Heidary, N., Naik, H., Burgin, S.
Journal of the American Academy of Dermatology. 2008; 58(4): 545-570
[Pubmed]
14 Practical Management of Toxicities Associated with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Alfonso Quintás-Cardama,Jorge E. Cortés,Hagop Kantarjian
Clinical Lymphoma and Myeloma. 2008; 8: S82
[Pubmed] | [DOI]
15 Chemotherapeutic agents and the skin: An update
Noushin Heidary,Haley Naik,Susan Burgin
Journal of the American Academy of Dermatology. 2008; 58(4): 545
[Pubmed] | [DOI]
16 Imatinib-induced Stevens-Johnson syndrome: Recurrence after re-challenge with a lower dose
Mahapatra M, Mishra P, Kumar R
Annals of Hematology. 2007; 86(7): 537-538
[Pubmed]
17 Imatinib-induced Stevens–Johnson syndrome: recurrence after re-challenge with a lower dose
Manoranjan Mahapatra,Pravas Mishra,Rajat Kumar
Annals of Hematology. 2007; 86(7): 537
[Pubmed] | [DOI]



 

Top
Print this article  Email this article
Previous article Next article

    

Online since 15th March '04
Published by Wolters Kluwer - Medknow